^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
andamertinib (PLB1004)
i
Other names: PLB1004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Avistone Biotech
Drug class:
EGFR inhibitor
Related drugs:
17d
Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study. (PubMed, J Thorac Oncol)
Andamertinib at 240 mg once daily demonstrated efficacy with a manageable safety profile in previously treated patients with EGFR ex20ins-mutant NSCLC.
P2 data • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
andamertinib (PLB1004)
1m
Phase III clinical study of EGFR 20 exon insertion mutation in PLB1004 non-small cell lung cancer (ChiCTR2500107929)
P3, N=327, Recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
New P3 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR positive
|
cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • andamertinib (PLB1004)
4ms
An open-label, multicenter, phase Ib/II clinical study to evaluate the safety, efficacy and pharmacokinetic characteristics of PLB1004 capsules in combination with platinum-based doublet chemotherapy in subjects with EGFR mutation-positive non-small cell lung cancer. (ChiCTR2500105771)
P1/2, N=108, Not yet recruiting, Shanghai Chest Hospital; Avistone Pharmaceutical(Ningbo)Co., LTD.
New P1/2 trial
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
andamertinib (PLB1004)
6ms
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (clinicaltrials.gov)
P3, N=327, Enrolling by invitation, Avistone Biotechnology Co., Ltd. | Not yet recruiting --> Enrolling by invitation
Enrollment open
|
cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • andamertinib (PLB1004)
7ms
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (clinicaltrials.gov)
P1/2, N=156, Recruiting, Avistone Biotechnology Co., Ltd. | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
bozitinib (APL-101) • andamertinib (PLB1004)
7ms
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure (clinicaltrials.gov)
P3, N=278, Not yet recruiting, Avistone Biotechnology Co., Ltd.
New P3 trial
|
cisplatin • carboplatin • pemetrexed • bozitinib (APL-101) • andamertinib (PLB1004)
8ms
Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd. | Trial completion date: Sep 2026 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
andamertinib (PLB1004)
1year
Kannon: A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR Ex20ins Mutation Patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov)
P2, N=157, Recruiting, Avistone Biotechnology Co., Ltd. | Trial primary completion date: Apr 2024 --> Oct 2024
Trial primary completion date • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
andamertinib (PLB1004)
over1year
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. (clinicaltrials.gov)
P2, N=120, Recruiting, Avistone Biotechnology Co., Ltd.
New P2 trial • Metastases
|
Tagrisso (osimertinib) • bozitinib (APL-101) • andamertinib (PLB1004)
over1year
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1, N=81, Recruiting, Avistone Biotechnology Co., Ltd. | Active, not recruiting --> Recruiting | Initiation date: Nov 2023 --> Jul 2024
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
andamertinib (PLB1004)
over1year
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (clinicaltrials.gov)
P1/2, N=156, Recruiting, Avistone Biotechnology Co., Ltd.
New P1/2 trial
|
bozitinib (APL-101) • andamertinib (PLB1004)
almost2years
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. (clinicaltrials.gov)
P3, N=327, Not yet recruiting, Avistone Biotechnology Co., Ltd.
New P3 trial
|
EGFR (Epidermal growth factor receptor)
|
cisplatin • carboplatin • Tyvyt (sintilimab) • pemetrexed • andamertinib (PLB1004)
Share via
